Lallemand Health Solutions is proud to partner with Kirin Holdings to bring IMMUSE® to a broader global audience. IMMUSE is a heat-inactivated Lactococcus lactis strain Plasma, developed by Kirin and backed by 15 clinical studies. It’s one of the most thoroughly researched postbiotics available today, offering a unique approach to immune support.
IMMUSE works by directly activating plasmacytoid dendritic cells—key players in both innate and adaptive immunity. This distinctive mode of action has shown benefits across various health areas, including reduced cold-like symptoms, improved antiviral responses, and even enhanced athletic performance.
With consumer interest in immune health on the rise, IMMUSE is well-positioned to meet market demand. Available in multiple dosage formats, it’s easy to integrate into daily routines and product lines.
This partnership combines Kirin’s 130+ years of fermentation expertise and nearly four decades of immunity research with Lallemand’s 90 years of experience in microbial solutions. Together, we’re committed to delivering science-backed, innovative health ingredients to consumers worldwide.
Visit us at SupplySide Global in Las Vegas, USA, booth #5745, to learn how Immuse® can elevate your product offerings—or reach out at healthsolutions@lallemand.com.
